---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-014806"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:41:14.833020+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M

## Summary
- FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.
- Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.
- Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.
- Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.
- CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds.

## SEC filing metadata
- accession: 0001062993-25-014806
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/0001062993-25-014806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-014806
- JSON: https://secwatch.observer/filing/0001062993-25-014806.json
- Plain text: https://secwatch.observer/filing/0001062993-25-014806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.